BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23320105)

  • 1. Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis.
    Tibolla G; Piñeiro R; Chiozzotto D; Mavrommati I; Wheeler AP; Norata GD; Catapano AL; Maffucci T; Falasca M
    PLoS One; 2013; 8(1):e53808. PubMed ID: 23320105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential role of class II phosphatidylinositol-3-kinase-C2α in sphingosine 1-phosphate receptor-1-mediated signaling and migration in endothelial cells.
    Biswas K; Yoshioka K; Asanuma K; Okamoto Y; Takuwa N; Sasaki T; Takuwa Y
    J Biol Chem; 2013 Jan; 288(4):2325-39. PubMed ID: 23192342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The class II phosphoinositide 3-kinases PI3K-C2α and PI3K-C2β differentially regulate clathrin-dependent pinocytosis in human vascular endothelial cells.
    Aung KT; Yoshioka K; Aki S; Ishimaru K; Takuwa N; Takuwa Y
    J Physiol Sci; 2019 Mar; 69(2):263-280. PubMed ID: 30374841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.
    Mavrommati I; Cisse O; Falasca M; Maffucci T
    Sci Rep; 2016 Mar; 6():23277. PubMed ID: 26983806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine kinase activation regulates hepatocyte growth factor induced migration of endothelial cells.
    Duan HF; Wu CT; Lu Y; Wang H; Liu HJ; Zhang QW; Jia XX; Lu ZZ; Wang LS
    Exp Cell Res; 2004 Aug; 298(2):593-601. PubMed ID: 15265705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration.
    Maffucci T; Cooke FT; Foster FM; Traer CJ; Fry MJ; Falasca M
    J Cell Biol; 2005 Jun; 169(5):789-99. PubMed ID: 15928202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K-C2β limits mTORC1 signaling and angiogenic growth.
    Kobialka P; Llena J; Deleyto-Seldas N; Munar-Gelabert M; Dengra JA; Villacampa P; Albinyà-Pedrós A; Muixi L; Andrade J; van Splunder H; Angulo-Urarte A; Potente M; Grego-Bessa J; Castillo SD; Vanhaesebroeck B; Efeyan A; Graupera M
    Sci Signal; 2023 Nov; 16(813):eadg1913. PubMed ID: 38015911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rac1 modulates sphingosine 1-phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells.
    Gonzalez E; Kou R; Michel T
    J Biol Chem; 2006 Feb; 281(6):3210-6. PubMed ID: 16339142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overlapping and distinct roles for PI3Kbeta and gamma isoforms in S1P-induced migration of human and mouse endothelial cells.
    Heller R; Chang Q; Ehrlich G; Hsieh SN; Schoenwaelder SM; Kuhlencordt PJ; Preissner KT; Hirsch E; Wetzker R
    Cardiovasc Res; 2008 Oct; 80(1):96-105. PubMed ID: 18558630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class II PI3Ks α and β Are Required for Rho-Dependent Uterine Smooth Muscle Contraction and Parturition in Mice.
    Sarker MAK; Aki S; Yoshioka K; Kuno K; Okamoto Y; Ishimaru K; Takuwa N; Takuwa Y
    Endocrinology; 2019 Jan; 160(1):235-248. PubMed ID: 30476019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingosine-1-phosphate markedly induces matrix metalloproteinase and integrin-dependent human endothelial cell invasion and lumen formation in three-dimensional collagen and fibrin matrices.
    Bayless KJ; Davis GE
    Biochem Biophys Res Commun; 2003 Dec; 312(4):903-13. PubMed ID: 14651957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Overview of Class II Phosphoinositide 3-Kinases.
    Heng EYZ; Maffucci T
    Curr Top Microbiol Immunol; 2022; 436():51-68. PubMed ID: 36243839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3-kinase class II α-isoform PI3K-C2α is required for transforming growth factor β-induced Smad signaling in endothelial cells.
    Aki S; Yoshioka K; Okamoto Y; Takuwa N; Takuwa Y
    J Biol Chem; 2015 Mar; 290(10):6086-105. PubMed ID: 25614622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The class II phosphoinositide 3-kinase C2beta is not essential for epidermal differentiation.
    Harada K; Truong AB; Cai T; Khavari PA
    Mol Cell Biol; 2005 Dec; 25(24):11122-30. PubMed ID: 16314532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class II PI3K Functions in Cell Biology and Disease.
    Gulluni F; De Santis MC; Margaria JP; Martini M; Hirsch E
    Trends Cell Biol; 2019 Apr; 29(4):339-359. PubMed ID: 30691999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.
    Graupera M; Guillermet-Guibert J; Foukas LC; Phng LK; Cain RJ; Salpekar A; Pearce W; Meek S; Millan J; Cutillas PR; Smith AJ; Ridley AJ; Ruhrberg C; Gerhardt H; Vanhaesebroeck B
    Nature; 2008 May; 453(7195):662-6. PubMed ID: 18449193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class II phosphatidylinositol 3-kinase isoforms in vesicular trafficking.
    Yoshioka K
    Biochem Soc Trans; 2021 Apr; 49(2):893-901. PubMed ID: 33666217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K signalling in inflammation.
    Hawkins PT; Stephens LR
    Biochim Biophys Acta; 2015 Jun; 1851(6):882-97. PubMed ID: 25514767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis for Highly Selective Class II Alpha Phosphoinositide-3-Kinase Inhibition.
    Kücükdisli M; Bel-Abed H; Cirillo D; Lo WT; Efrém NL; Horatscheck A; Perepelittchenko L; Prokofeva P; Ehret TAL; Radetzki S; Neuenschwander M; Specker E; Médard G; Müller S; Wilhelm S; Kuster B; von Kries JP; Haucke V; Nazaré M
    J Med Chem; 2023 Oct; 66(20):14278-14302. PubMed ID: 37819647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.
    Chikh A; Ferro R; Abbott JJ; Piñeiro R; Buus R; Iezzi M; Ricci F; Bergamaschi D; Ostano P; Chiorino G; Lattanzio R; Broggini M; Piantelli M; Maffucci T; Falasca M
    Oncotarget; 2016 Apr; 7(14):18325-45. PubMed ID: 26934321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.